At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 731 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Placebo for Obesity and Heart Failure With Preserved Ejection Fraction (HFpEF). Completed, enrolled 731 participants across 146 sites in 10 countries.
Detailed Summary
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Brazil, China, India, Israel, Mexico, Puerto Rico, Russia, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartApr 2021
Primary CompletionJul 2024
TodayJul 2026
First PostedApr 19, 2021
Enrollment StartApr 20, 2021
Primary CompletionJul 2, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.2 years ago
Interventions
Tirzepatidedrug
Administered SC
Placeboother
Administered SC